Загрузка...
HOUT-17. ELDERLY PATIENTS >65YEARS OF AGE WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME GAIN LIFE TIME FROM TREATMENT WITH TUMOR TREATING FIELDS AND TEMOZOLOMIDE
BACKGROUND: The EF-14 trial was the first randomized controlled trial to report a survival benefit for newly diagnosed GBM patients in more than a decade with a survival rate greater than 10% at 5-years. A post hoc subgroup analysis of the elderly (>65 years) EF-14 population showed the greatest...
Сохранить в:
| Опубликовано в: : | Neuro Oncol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217141/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.485 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|